Cure My Disease

Don't miss your cure!

 Log in / Sign up

A single blood test may reveal whether a gene tied to transplant outcomes influences psoriatic arthritis risk.

NCT ID NCT07718815

Recruiting now Knowledge-focused Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

First seen Jul 22, 2026 · Last updated Jul 23, 2026 · Updated 1 time

Summary

This study compares the prevalence of the HLA B leader gene in 658 people with psoriatic arthritis and a healthy control group. Researchers will also look at the related HLA B27 gene. The goal is to see whether this genetic marker, already known to affect outcomes in bone marrow transplants, is more common in people with psoriatic arthritis. Participants provide one extra blood sample for genetic testing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
blood test for genetic analysis
What this could lead to
If a link is found, the HLA B leader gene could become a new target for understanding or treating psoriatic arthritis.
What could go wrong
This is an observational study, not a treatment trial. It may find no meaningful difference between groups, and even if it does, the practical implications are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HLA B LEADER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HLA B LEADER HLA B27 PSORIATIC ARTHRITIS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU Amiens Picardie

    RECRUITING

    Amiens, Picardie, 80054, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.